AzTrials
AzTrials

CancerPhase 1/2NCT04669899

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

A Phase 1/2 study testing JTX-8064 and pimivalimab in people with Cancer, run by Jounce Therapeutics, Inc. at 45 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cancer
What is being tested?
JTX-8064 and pimivalimab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
190 participants
Where
45 sitesUnited States
Study dates
12 Jan 2021to 28 Nov 2023
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Able and willing to participate and comply with all study requirements and provide signed and dated informed consent prior to initiation of any study procedures;
  • Histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancy:
  • Stages 1 and 2: Subjects must have received, have been intolerant to, have been ineligible for, or have declined all treatment known to confer clinical benefit with the exception of subjects enrolled in combination cohorts with a PD-1i, where a PD-1i is approved by the local regulatory agencies;
  • Stage 3: This stage may enroll subjects with 3L/4L PD-(L)1-naïve, platinum-resistant ovarian cancer;
  • Stage 4: This stage may enroll subjects with the following cancers:
  • 2L/3L ccRCC. Subjects must have progressed on or after treatment with an anti-PD-(L)1 agent in their most recent prior line of therapy;
Show all 21Show fewer
  • 2L-4L TNBC. Subjects must have progressed on or after treatment with a prior anti-PD-(L)1 therapy;
  • 1L, PD-(L)1-naïve, PD-L1+; combined positive score (CPS) ≥1% HNSCC;
  • 2L/3L platinum-experienced HNSCC. Subjects must have progressed on or after treatment with an anti-PD-(L)1-agent in their most recent prior line of therapy;
  • 3L/4L, PD-(L)1-naïve, platinum-resistant ovarian cancer;
  • 2L/3L NSCLC. Subjects must have progressed on or after treatment with platinum-based chemotherapy and an anti-PD-(L)1-containing therapy. The anti-PD-(L)1 agent must have been a part of the most recent prior line of therapy. Subjects with EGFR mutations and ALK rearrangements will be excluded. Subjects with other targetable genomic aberrations for which FDA approved therapies exist must have received appropriate FDA-approved targeted therapy;
  • 2L/3L cSCC. Subjects must have progressed on or after treatment with an anti-PD-(L)1 agent in their most recent prior line of therapy;
  • 2L-4L PD-(L)1-naïve undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS);
  • 2L/3L biliary tract cancer (BTC), including intra- and extra-hepatic biliary duct cancer and cancer of the gallbladder. Subjects must have progressed on or after gemcitabine/cisplatin (Gem/Cis) in the metastatic setting and must have PD-(L)1 inhibitor resistance. Subjects with FGFR and IDH1 mutations must have progressed on or after targeted therapies for these mutations;
  • Measurable disease, according to the RECIST version 1.1, that has objectively progressed since (or on) previous treatment as assessed by the Investigator;
  • ≥18 years of age;
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
  • Predicted life expectancy of ≥3 months;
  • Have specified laboratory values (obtained ≤28 days prior to planned Cycle 1, Day 1 [C1D1]) in accordance with the study protocol;
  • For women of childbearing potential (WOCBP): negative serum pregnancy test during the Screening period and a negative urine pregnancy test up to 24 hours in advance of C1D1;
  • WOCBP and males whose partners are WOCBP must agree to use a highly effective method of birth control throughout their participation and for 5 months following the last study drug administration.

Who cannot join

  • Concurrent anticancer treatment, either FDA approved or investigational, for the cancer being evaluated in this study or for prior malignancies. A past history of other malignancies is allowed as long as the subject is not receiving treatment other than hormonal therapy and, in the judgment of the Investigator, is unlikely to have a recurrence. Of note, concurrent malignancies that do not require treatment and are clinically stable are allowed;
  • Prior infusion of JTX-8064, LILRB2, or ILT4-directed therapy;
  • The therapies listed below within the specified timeframe or ongoing toxicity attributed to prior therapy that was >Grade 1 according to the NCI CTCAE, version 5.0. Exceptions: >Grade 1 toxicities that, in the opinion of the Investigator, should not exclude the subject (e.g., alopecia, Grade 2 neuropathy, hypo- or hyperthyroidism, or other endocrinopathies that are well controlled with hormone replacement) and are approved by the Medical Monitor:
  • Major surgery (excluding minor procedures, for example, placement of vascular access, gastrointestinal/biliary stent, biopsy) <4 weeks prior to planned C1D1;
  • Immunotherapy or biologic therapy <28 days prior to planned C1D1 or 5 half-lives, whichever is shorter;
  • Chemotherapy <21 days prior to planned C1D1, or <42 days for mitomycin or nitrosoureas or 5 half-lives, whichever is shorter;
Show all 23Show fewer
  • Targeted small molecule therapy <14 days or 5 half-lives, whichever is shorter, prior to planned C1D1;
  • Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started <14 days prior to planned C1D1 are not permitted; however, antiestrogen therapy, bisphosphonates, somatostatin analogues, leuprolide, and denosumab are permitted if started ≥14 days prior to C1D1. Other hormonal treatments and/or treatment for stable cancers (other than the cancer being treated on-study) may also be permitted 1) if these therapies would not be expected to have any positive or negative effect on the cancer being treated and 2) if discussed with and approved by the Medical Monitor;
  • Radiation therapy <21 days prior to planned C1D1. Exception: Limited (e.g., pain palliation) radiation therapy is allowed prior to and during study drug administration as long as there are no acute toxicities, any AE due to prior radiation therapy has recovered to <Grade 2, and the radiation is not administered to a target lesion;
  • Any prior organ transplantation, including allogeneic or autologous stem cell transplantation;
  • History of intolerance, hypersensitivity, or treatment discontinuation due to Grade 3 or greater irAEs (related to prior immunotherapy);
  • Diagnosis of immunodeficiency, either primary or acquired, or treatment with immunosuppressive levels of systemic corticosteroids (equivalent to ≥10 mg prednisone per day) or any other form of immunosuppressive therapy within 7 days prior to planned C1D1. Exception: Inhaled, intra-articular, topical, or systemic corticosteroids (systemic only at doses intended for adrenal replacement) and doses of immunosuppressive agents used prophylactically for contrast allergies are permitted in the absence of active autoimmune disease;
  • Known severe intolerance or life-threatening hypersensitivity reactions to humanized mAbs or IV immunoglobulin preparations; any history of anaphylaxis; known allergy to any of the study medications, their analogues, or excipients (sodium acetate, sucrose, sodium chloride and polysorbate 80) in the various formulations of any agent;
  • Symptomatic or uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation (brain metastases that are stable and asymptomatic after prior treatment will be allowed);
  • Active and clinically relevant bacterial, fungal, or viral infection, including known hepatitis A, B, or C, or HIV (testing not required);
  • Women who are pregnant or breastfeeding or who plan to become pregnant/breastfeed while on study; men who plan to father children during the study;
  • History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or severe (≥Grade 3) radiation pneumonitis (excluding localized radiation pneumonitis);
  • History in the last 3 months of acute diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction, unless approved by Medical Monitor;
  • Symptomatic cardiac or cerebrovascular disease that is unresponsive to surgical or medical management;
  • Medical or social condition that, in the opinion of the Investigator, might place the subject at increased risk, adversely affect compliance, or confound safety or other clinical study data interpretation;
  • Active disease requiring systemic immunosuppressive therapy;
  • Live vaccines ≤30 days of C1D1;
  • Deep vein thrombosis, pulmonary embolism (including asymptomatic pulmonary embolism identified on imaging), or other thromboembolic event within the 6 months preceding C1D1 for JTX-8064 monotherapy cohorts only.

Trial locations and contacts

45 sites in 1 country.

45 sites in 1 country

United States45 sites

  • University of Michigan

    Ann Arbor, Michigan, 48109

  • Augusta Oncology Associates - Wheeler Road

    Augusta, Georgia, 30909

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35249

  • Gabrail Cancer Center

    Canton, Ohio, 44718

  • University of Chicago

    Chicago, Illinois, 60637

  • UC Health, LLC

    Cincinnati, Ohio, 45229

  • Case Comprehensive Cancer Center

    Cleveland, Ohio, 44106

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230

  • Cancer Care Center of Decatur

    Decatur, Illinois, 62526

  • Barbara Ann Karmanos Cancer Center

    Detroit, Michigan, 48201

  • Henry Ford Hospital

    Detroit, Michigan, 48202

  • City of Hope

    Duarte, California, 91010

  • University of Florida

    Gainesville, Florida, 32610

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234

  • START Midwest -Cancer & Hematology Center of Western Michigan

    Grand Rapids, Michigan, 49546

  • Prisma Health

    Greenville, South Carolina, 29605

  • Oncology Consultants, P.A.

    Houston, Texas, 77024

  • MD Anderson

    Houston, Texas, 77030

  • Carolina BioOncology

    Huntersville, North Carolina, 28708

  • California Cancer Associates for Research & Excellence, Inc.

    La Jolla, California, 92037

  • University of California, San Diego

    La Jolla, California, 92093

  • University of Kentucky Chandler Medical Center (UKCMC)

    Lexington, Kentucky, 40536

  • University of Arkansas Medical Sciences

    Little Rock, Arkansas, 72205

  • Cedars Sinai

    Los Angeles, California, 90048

  • Joe Arrington Cancer Research & Treatment Center

    Lubbock, Texas, 79410

  • The Board of Regents of the University of Wisconsin

    Madison, Wisconsin, 53792

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226

  • Regents of the University of Minnesota

    Minneapolis, Minnesota, 55455

  • Yale University

    New Haven, Connecticut, 06519

  • Weill Cornell

    New York, New York, 10021

  • Mount Sinai

    New York, New York, 10029

  • Montefiore Medical Center PRIME

    New York, New York, 10461

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104

  • UC Irvine Medical Center

    Orange, California, 92868

  • Adventist Health System/Sunbelt, Inc.

    Orlando, Florida, 32803

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111

  • Providence Portland Cancer Center

    Portland, Oregon, 97213

  • University of California, Davis

    Sacramento, California, 95817

  • START Texas Accelerated Research Therapeutics

    San Antonio, Texas, 78229

  • Seattle Cancer Care Alliance

    Seattle, Washington, 98331

  • Tampa General Hospital

    Tampa, Florida, 33606

  • Arizona Clinical Research Center

    Tucson, Arizona, 85258

  • Georgetown University

    Washington D.C., District of Columbia, 20057

  • START Mountain Region

    West Valley City, Utah, 84119

Other trials in United States

About this study

Official title: Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i).

Read the detailed description

JTX-8064 is a humanized mAb designed to block the interaction of LILRB2 with its known ligands, endogenous major histocompatibility complex class I (MHC I) molecules. This is a Phase 1/2, first in human, open label, multicenter, dose escalation and dose expansion clinical trial to determine the safety, tolerability, maximum tolerated dose (MTD) and RP2D of JTX-8064 when administered as a single agent and in combination with a PD-1i in adult subjects with advanced refractory solid tumor malignancies. Additionally, the study will seek to evaluate the pharmacokinetics and immunogenicity of JTX-8064, and preliminary efficacy of JTX-8064 as a monotherapy and in combination with a PD-1i.

Conditions
Cancer
Being tested
JTX-8064, pimivalimab
Keywords
JTX-8064, LILRB2, ILT4, PD-1, JTX-4014, Immunotherapy, Immuno-oncology, Solid tumor Malignancies, Dose escalation, INNATE, Monotherapy, Combination Therapy, Antineoplastic Agents, Immunological
Medical subject headings
Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • JTX-8064Drug

    Also called Anti-LILRB2, Anti-ILT4

    Specified dose on specified days

  • pimivalimabDrug

    Also called JTX-4014, Anti-PD-1

    Specified dose on specified days

Study groups in NCT04669899
Study groupRoleWhat they receive
Stage 1, Dose Escalation: JTX-8064 monotherapy dose escalationExperimentalDose Escalation, Stage 1: JTX-8064 Monotherapy. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies.
Receives: Drug: JTX-8064
Stage 2, Dose Escalation: JTX-8064 in combination with pimivalimabExperimentalDose Escalation, Stage 2: JTX-8064 in combination with pimivalimab. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies.
Receives: Drug: JTX-8064; Drug: pimivalimab
Stage 3 Expansion: JTX-8064 monotherapy (Ovarian)ExperimentalCohort will enroll subjects with advanced/metastatic PD-1/PD-L1 (PD-(L)1)-naïve, platinum-resistant ovarian cancer.
Receives: Drug: JTX-8064
Stage 4, Expansion: JTX-8064 in combination with pimivalimab (ccRCC)ExperimentalJTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced clear cell renal cell carcinoma (ccRCC).
Receives: Drug: JTX-8064; Drug: pimivalimab
Stage 4, Expansion: JTX-8064 in combination with pimivalimab (TNBC)ExperimentalJTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced triple negative breast cancer (TNBC).
Receives: Drug: JTX-8064; Drug: pimivalimab
Stage 4, Expansion: JTX-8064 in combination with pimivalimab (HNSCC)ExperimentalJTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, PD-L1+ head and neck squamous cell carcinoma (HNSCC).
Receives: Drug: JTX-8064; Drug: pimivalimab
Stage 4, Expansion: JTX-8064 in combination with pimivalimab (Ovarian)ExperimentalJTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, platinum-resistant ovarian cancer.
Receives: Drug: JTX-8064; Drug: pimivalimab
Stage 4, Expansion: JTX-8064 in combination with pimivalimab (NSCLC)ExperimentalJTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced non-small cell lung cancer (NSCLC).
Receives: Drug: JTX-8064; Drug: pimivalimab
Stage 4, Expansion: JTX-8064 in combination with pimivalimab (cSCC)ExperimentalJTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced cutaneous squamous cell carcinoma (cSCC).
Receives: Drug: JTX-8064; Drug: pimivalimab
Stage 4, Expansion: JTX-8064 in combination with pimivalimab (UPS & LPS)ExperimentalJTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS).
Receives: Drug: JTX-8064; Drug: pimivalimab
Stage 4, Expansion: JTX-8064 in combination with pimivalimab (PD-(L)1i-experienced HNSCC)ExperimentalJTX-8064 in combination with pimivalimab. Cohort will enroll subjects with PD-(L)1i-experienced HNSCC.
Receives: Drug: JTX-8064; Drug: pimivalimab
Stage 4, Expansion: JTX-8064 in combination with pimivalimab (BTC)ExperimentalJTX-8064 in combination with pimivalimab. Cohort will enroll subjects with biliary tract cancer (BTC), including intra-and extra-hepatic biliary duct cancer and cancer of the gallbladder. All subjects must have progressed on or after gemcitabine/cisplatin (Gem/Cis) in the metastatic setting, must have PD-(L)1i resistance.
Receives: Drug: JTX-8064; Drug: pimivalimab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence and severity of DLTs, treatment-emergent adverse events (TEAEs), serious TEAEs, and discontinuation due to adverse events (AEs) evaluated using National Cancer Institute (NCI) Common Technology Criteria for Adverse Events (CTCAE) version 5.0

    Measured: up to 24 months

  2. Determination of a RP2D for JTX-8064 monotherapy and in combination with a PD-1i

    Measured: up to 24 months

Secondary outcomes (16)

  1. Cmax (the maximum observed concentration) for JTX-8064 monotherapy and in combination with a PD-1i

    Measured: Cycles 1 through 12 (each cycle is 21 days)

  2. Tmax (time of maximum observed concentration) for JTX-8064 monotherapy and in combination with a PD-1i

    Measured: Cycles 1 through 12 (each cycle is 21 days)

  3. Cmin for JTX-8064 monotherapy and in combination with a PD-1i

    Measured: Cycles 1 through 12 (each cycle is 21 days)

  4. AUClast (area under the concentration-time curve from time 0 to the last measurable concentration) for JTX-8064 monotherapy and in combination with a PD-1i

    Measured: Cycles 1 and 3 (each cycle is 21 days)

  5. Cmax for PD-1i in combination with JTX-8064

    Measured: Cycles 1 through 12 (each cycle is 21 days)

  6. Tmax for PD-1i in combination with JTX-8064

    Measured: Cycles 1 through 12 (each cycle is 21 days)

  7. Cmin for PD-1i in combination with JTX-8064

    Measured: Cycles 1 through 12 (each cycle is 21 days)

  8. Incidence of anti-drug antibodies (ADAs) to JTX-8064 and, as appropriate, to PD-1i

    Measured: Baseline through Cycle 12 (each cycle is 21 days)

  9. Incidence of neutralizing antibodies (Nabs) to JTX-8064 and, as appropriate, to PD-1i

    Measured: Baseline through Cycle 12 (each cycle is 21 days)

  10. For Stages 1 and 2: Receptor occupancy for LILRB2 on monocytes in whole blood

    Measured: Baseline through Cycle 6 (each cycle is 21 days)

  11. For Stages 3 and 4: Preliminary efficacy endpoints: Objective response rate (ORR; the proportion of subjects who have had a partial response [PR] or complete response [CR]) as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Measured: up to 36 months

  12. For Stages 3 and 4: Preliminary efficacy endpoints: Disease control rate (DCR; the proportion of subjects who have a PR, CR, or stable disease [SD]), as per RECIST version 1.1

    Measured: up to 36 months

  13. For Stages 3 and 4: Preliminary efficacy endpoints: Progression-free survival (PFS; the interval from start of treatment to the earlier of first documentation of disease progression or death from any cause)

    Measured: up to 36 months

  14. For Stages 3 and 4: Preliminary efficacy endpoints: Overall survival (OS; the interval from start of treatment to death of any cause)

    Measured: up to 36 months

  15. For Stages 3 and 4: Preliminary efficacy endpoints: Duration of response (DOR; the time from documentation of tumor progression or death due to any cause, whichever comes first)

    Measured: up to 36 months

  16. For Stages 3 and 4: Preliminary efficacy endpoints: Percentage of subjects with tumor reduction at any time

    Measured: up to 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2020
  2. Study start12 Jan 2021
  3. Primary completion28 Nov 2023
  4. Study completion28 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
190 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04669899
Sponsor's protocol ID
JTX-8064-101
Status last verified
Apr 2024
First submitted
4 Dec 2020
Last updated
9 Apr 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing JTX-8064 and pimivalimab in people with Cancer, run by Jounce Therapeutics, Inc. at 45 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 45 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence and severity of DLTs, treatment-emergent adverse events (TEAEs), serious TEAEs, and discontinuation due to adverse events (AEs) evaluated using National Cancer Institute (NCI) Common Technology Criteria for Adverse Events (CTCAE) version 5.0 (time frame: up to 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04669899.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in